<?xml version="1.0" encoding="UTF-8"?>
<p id="Par35">If the product shows efficacy in early clinical studies, a rapid increase in capacity would be needed. Process transfer to more manufacturing sites and/or scale-up of the phase 1 process would be the fastest ways to achieve this objective.</p>
